
    
      The open-label prospective randomized clinical trial compares subcutaneous LMWH (tinzaparin)
      administered for 6 months versus initial treatment using subcutaneous LMWH followed by oral
      anticoagulants given for 6 months in patients with acute venous thrombosis.

      To evaluate the direct and indirect cost of each treatment regimen in a rural population
      environment.
    
  